Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study
de Groot, Joris R.; Weiss, T. W.; Kelly, Peter; Monteiro, Pedro; Deharo, Jean Claude; de Asmundis, C.; López-de-Sá, Esteban; Waltenberger, Johannes; Steffel, Jan; Lévy, Pierre; Bakhai, Ameet; Zierhut, Wolfgang; Laeis, Petra; Manu, M. C.; Reimitz, Paul-Egbert; De Caterina, R.; Kirchhof, Paulus (2021), Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study, European Heart Journal - Cardiovascular Pharmacotherapy, 7, FI1, p. f30-f39. 10.1093/ehjcvp/pvaa079
TypeArticle accepté pour publication ou publié
Nom de la revueEuropean Heart Journal - Cardiovascular Pharmacotherapy
MétadonnéesAfficher la notice complète
Auteur(s)de Groot, Joris R.
Weiss, T. W.
Deharo, Jean Claude
de Asmundis, C.
Laboratoire d'Economie de Dauphine [LEDa]
Manu, M. C.
De Caterina, R.
Résumé (EN)Aims : Non-vitamin K oral anticoagulants are safe and effective for stroke prevention in patients with atrial fibrillation (AF). Data on the safety and efficacy of edoxaban in routine care are limited in Europe. We report 1-year outcomes in patients with AF treated with edoxaban in routine care. Methods and results : ETNA-AF-Europe is a prospective, multicentre, post-authorization, observational study enrolling patients treated with edoxaban in 10 European countries, the design of which was agreed with the European Medicines Agency as part of edoxaban’s post-approval safety plan. Altogether 13 092 patients in 852 sites completed the 1-year follow-up [mean age: 73.6 ± 9.5 years ; 57% male, mean follow-up: 352 ± 49 days (median: 366 days)]. Most patients had associated comorbidities (mean CHA2DS2-VASc score: 3.1 ± 1.4). Stroke or systemic embolism was reported in 103 patients (annualized event rate : 0.82%/year), and major bleeding events were reported in 132 patients (1.05%/year). Rates of intracranial haemorrhage were low [30 patients (0.24%/year)]. Death occurred in 442 patients (3.50%/year); cardiovascular (CV) death occurred in 206 patients (1.63%/year). The approved dosing of edoxaban was chosen in 83%. All-cause and CV mortality were higher in patients receiving edoxaban 30 mg vs. 60 mg, in line with the higher age and more frequent comorbidities of the 30 mg group. Major bleeding was also numerically more common in patients receiving edoxaban 30 mg vs. 60 mg. Conclusion : The rates of stroke, systemic embolism, and major bleeding are low in this large unselected cohort of high-risk AF patients routinely treated with edoxaban.
Mots-clésNon-vitamin K oral anticoagulant; Edoxaban; Real-world; Registry; Atrial fibrillation; mortality; stroke prevention, cerebrovascular accident
Affichage des éléments liés par titre et auteur.
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study De Caterina, Raffaele; Kelly, Peter; Monteiro, Pedro; Deharo, Jean Claude; de Asmundis, Carlo; López-de-Sá, Esteban; Weiss, Thomas W.; Waltenberger, Johannes; Steffel, Jan; de Groot, Joris R.; Lévy, Pierre; Bakhai, Ameet; Zierhut, Wolfgang; Laeis, Petra; Reimitz, Paul-Egbert; Kirchhof, Paulus (2019) Article accepté pour publication ou publié
Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study Cohen, Alexander T.; Ay, Cihan; Hainaut, Philippe; Décousus, Hervé; Hoffmann, Ulrich; Gaine, Sean; Coppens, Michiel; da Silva, Pedro Marques; Jiménez, David; Amann-Vesti, Beatrice; Brüggenjürgen, Bernd; Lévy, Pierre; Bastida, Julio Lopez; Vicaut, Eric; Laeis, Petra; Fronk, Eva-Maria; Zierhut, Wolfgang; Malzer, Thomas; Bramlage, Peter; Agnelli, Giancarlo (2018) Article accepté pour publication ou publié
Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK Bowrin, Kevin; Briere, Jean-Baptiste; Lévy, Pierre; Millier, Aurélie; Tardu, Jean; Toumi, Mondher (2020-06) Article accepté pour publication ou publié
Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective Lévy, Pierre; Smadja, David M.; Dorey, Julie; Toumi, Mondher; Meinecke, Anna-Katharina; Bowrin, Kevin; Briere, Jean-Baptiste (2019) Article accepté pour publication ou publié
Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: A prospective multicentric cohort study Ferrier, Clement; Thébaut, Clémence; Lévy, Pierre; Baffert, Sandrine; Asselain, Bernard; Rouzier, Roman; Hequet, Delphine (2020-07) Article accepté pour publication ou publié